Press Releases

Eyenuk Supports Federal Efforts to Promote Nationwide Adoption of Interoperable Standards for Ophthalmic Imaging Data

LOS ANGELES, November 28th, 2023 โ€“ Eyenuk, Inc., a leading global digital health company specializing in artificial intelligence (AI), today stands shoulder to shoulder with the National Eye Institute (NEI), โ€ฆ

Eyenuk Supports Federal Efforts to Promote Nationwide Adoption of Interoperable Standards for Ophthalmic Imaging Data Read More ยป

New FDA Clearance Makes Eyenuk the First Company with Multiple Cameras for Autonomous AI Detection of Diabetic Retinopathy

This clearance expands the label of its flagship product, the EyeArtยฎ AI system, broadening the choice for primary care clinics to screen people with diabetes Companyโ€™s FDA clearance also includes โ€ฆ

New FDA Clearance Makes Eyenuk the First Company with Multiple Cameras for Autonomous AI Detection of Diabetic Retinopathy Read More ยป

Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of Diabetic Retinopathy, Age-Related Macular Degeneration, and Glaucoma

The approval allows Eyenukโ€™s AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss LOS ANGELES, January 31, โ€ฆ

Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of Diabetic Retinopathy, Age-Related Macular Degeneration, and Glaucoma Read More ยป

Study Finds Eyenuk Artificial Intelligence Detects Diabetic Retinopathy with Far Greater Sensitivity than Ophthalmologistsโ€™ Dilated Exams

Academic leaders will review their experience with the technology during a symposium at AAO 2022, the American Academy of Ophthalmology annual meeting CHICAGO, September 30, 2022 โ€” From the American โ€ฆ

Study Finds Eyenuk Artificial Intelligence Detects Diabetic Retinopathy with Far Greater Sensitivity than Ophthalmologistsโ€™ Dilated Exams Read More ยป

Vision Loss Rehabilitation Canada brings AI-driven diabetic eye screening to rural and Indigenous communities

Program selects Eyenukโ€™s EyeArt AI system to make vision-saving screening more accessible in remote Ontario communities LOS ANGELES and TORONTO, August 16, 2022 โ€“ Vision Loss Rehabilitation Canada (VLRC), Canadaโ€™s โ€ฆ

Vision Loss Rehabilitation Canada brings AI-driven diabetic eye screening to rural and Indigenous communities Read More ยป

UK National Screening Committee Report Singles Out Eyenukโ€™s EyeArt as the Only Diabetic Eye Screening AI Technology Ready for Live Clinical Implementation in the National Health Service

LOS ANGELES, June 1, 2022 โ€“ Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screeningโ„ข and AI โ€ฆ

UK National Screening Committee Report Singles Out Eyenukโ€™s EyeArt as the Only Diabetic Eye Screening AI Technology Ready for Live Clinical Implementation in the National Health Service Read More ยป

Eyenuk Joins the Population Health Alliance, Paving Way for Autonomous AI to Improve Diabetes Complications

Harnessing Artificial Intelligence, Eyenuk is Focused on Improving Population Health Outcomes by Bringing Diabetes Complication Management to Point-of-Care and Community Settings    WASHINGTON, March 10, 2022 โ€“ Population Health Alliance โ€ฆ

Eyenuk Joins the Population Health Alliance, Paving Way for Autonomous AI to Improve Diabetes Complications Read More ยป

Eyenuk Announces Publication of Strong EyeArtยฎ Pivotal Clinical Trial Results in JAMA Network Open

The published results demonstrate exceptional EyeArt accuracy in a pre-registered, prospective, multicenter clinical trial Los Angeles, November 15, 2021 โ€” Eyenuk, Inc., a global artificial intelligence (AI) medical technology and โ€ฆ

Eyenuk Announces Publication of Strong EyeArtยฎ Pivotal Clinical Trial Results in JAMA Network Open Read More ยป

Eyenuk Applauds CMS CY 2022 Medicare Physician Fee Schedule Final Rule to Establish National Price for Autonomous AI Technology

 The CMS Final Rule establishes a national payment for CPT code 92229 that describes Eyenukโ€™s FDA-cleared EyeArtยฎ AI system and confirms that AI can be used to close care gaps โ€ฆ

Eyenuk Applauds CMS CY 2022 Medicare Physician Fee Schedule Final Rule to Establish National Price for Autonomous AI Technology Read More ยป

Eyenuk Announces $6.2 Million Financing to Accelerate Adoption of FDA-cleared AI Technology for Detection of Diabetic Retinopathy

Financing led by AXA IMโ€™s Impact Investing strategy Los Angeles, CA, July 20, 2021 โ€” Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader โ€ฆ

Eyenuk Announces $6.2 Million Financing to Accelerate Adoption of FDA-cleared AI Technology for Detection of Diabetic Retinopathy Read More ยป

Multinational Optical Retailer Piloting AI and Telemedicine Technology to Protect Community Eye Health During the COVID-19 Pandemic

Devlyn Optical Partnering with Eyenuk to Offer Diabetic Retinopathy Screening Los Angeles, CA, June 8, 2020 โ€” Eyenuk, Inc. and Devlyn Optical, a spin-off of Grupo Devlyn, a multinational optical โ€ฆ

Multinational Optical Retailer Piloting AI and Telemedicine Technology to Protect Community Eye Health During the COVID-19 Pandemic Read More ยป